Targeting PsA and the Evolving Role of JAK Inhibitors

Learn about the current treatment of psoriatic arthritis and related conditions. 




In this course, pharmacists will learn more about spondyloarthiritis and psoriatic arthritis, how they differ from rheumatoid arthritis, goals of therapy and an extensive review of the agents used to treat these conditions.

Learning objectives:

By the end of this course, you should be able to:  

  • Describe the classification of spondyloarthropathies (SpA) 
  • Discuss the patient impact of psoriatic arthritis (PsA) 
  • Screen for PsA in patients affected by musculoskeletal (MSK) symptoms and presenting with a typical clinical picture of non MSK manifestations (e.g., uveitis, inflammatory bowel disease, psoriasis) illustrating the multifaceted disease 
  • Recognize treatment options with a special focus on new and emerging therapies 
  • Educate patients regarding the different management options for people with PsA  

Course outline:

  • Introduction
  • Recording
  • Post lesson exam
  • Evaluation


Course at a glance:

  • 1.5 hours to complete
  • Course expiration date: January 2024
  • Online
  • Not accredited

Who should take this course:

Pharmacists who wish to expand their knowledge in the area of PsA and JAK Inhibitors. 

Development Team:

  • Carolyn Whiskin, BSc. Phm NCMP
  • Michael Boivin, BSc. Pharm
  • Ravina Sanghera-Grewal, BSc. Pharm, PharmD
  • Mark Hazeltine, MD, FRCPC